Date: 2012-06-04
Type of information: R&D agreement
Compound: DuoBody™ technology platform
Company: Genmab (Denmark) Novartis (Switerland)
Therapeutic area:
Type agreement: R&D
development
Action mechanism: The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies\' specificity and efficacy in inactivating the disease targets.
Disease:
Details: Genmab has announced an agreement with Novartis to use its DuoBody™ technology platform to create and develop bispecific antibodies. Genmab will create panels of bispecific antibodies to two disease target combinations identified by Novartis. All research work on the programs is fully funded by Novartis.
Financial terms: Under the terms of the agreement, Genmab receives an upfront payment of $ 2 million (approximately DKK 12 million). If all milestones in the agreement are achieved, the total potential value of the agreement to Genmab would be approximately $ 175 million (approximately DKK 1,055 million), plus research funding and royalties.
Latest news:
